Development of Nanoparticles to Deliver a CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy

被引：0
|
作者：
Emami, Michael R. [1 ,2 ,3 ]
Young, Courtney S. [1 ,2 ,3 ]
Ji, Ying [4 ,5 ]
Pyle, April D. [1 ,2 ,6 ]
Meng, Huan [4 ,5 ]
Spencer, Melissa J. [1 ,2 ,3 ]
机构：
[1] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Ctr Duchenne Muscular Dystrophy, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA
[4] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA USA
[5] Univ Calif Los Angeles, Div Nanomed, Med, Los Angeles, CA USA
[6] Univ Calif Los Angeles, Microbiol Immunol & Mol Genet, Los Angeles, CA USA
来源：
MOLECULAR THERAPY | 2018年 / 26卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
615
引用
收藏
页码：284 / 285
页数：2
相关论文
共 50 条
  • [21] Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
    Pickar-Oliver, Adrian
    Nelson, Christopher
    Bohning, Joel
    Gemberling, Matthew
    Bulaklak, Karen
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2019, 27 (04) : 180 - 181
  • [22] CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy
    Heather Wood
    Nature Reviews Neurology, 2015, 11 (4) : 184 - 184
  • [23] Assessment of Efficacy 6 Months After Systemic Injection of an AAV-CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
    Young, Courtney
    Gibbs, Elizabeth
    Perez, Jesus
    Emami, Michael
    Bengtsson, Niclas
    Chamberlain, Jeffrey
    Pyle, April
    Spencer, Melissa
    MOLECULAR THERAPY, 2022, 30 (04) : 491 - 491
  • [24] CRISPR/Cas9 mediated gene editing of Duchenne muscular dystrophy with a single gene deleted adenoviral vector
    Ehrke-Schulz, E.
    Mouly, V.
    Ehrhardt, A.
    HUMAN GENE THERAPY, 2019, 30 (11) : A161 - A161
  • [25] Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
    Mollanoori, Hasan
    Rahmati, Yazdan
    Hassani, Bita
    Mehr, Meysam Havasi
    Teimourian, Shahram
    GENES & DISEASES, 2021, 8 (02) : 146 - 156
  • [26] Spell-checking nature: interrogating the versatility of the CRISPR/Cas9 system for the treatment of Duchenne Muscular Dystrophy
    Wojtal, D.
    Kemaladewi, D. U.
    Malam, Z.
    Abdullah, S.
    Wong, T. W. Y.
    Hyatt, E.
    Pereira, S.
    Stavropoulos, J.
    Mouly, V.
    Mamchaoui, K.
    Muntoni, F.
    Voit, T.
    Gonorazky, H.
    Dowling, J. J.
    Mendoza-Londono, R.
    Ivakine, E.
    Cohn, R. D.
    HUMAN GENE THERAPY, 2015, 26 (10) : A15 - A15
  • [27] Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy
    Wong, Tatianna Wai Ying
    Cohn, Ronald D.
    CURRENT GENE THERAPY, 2017, 17 (04) : 301 - 308
  • [28] Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening 
    Patricia Soblechero-Martín
    Edurne Albiasu-Arteta
    Aina Anton-Martinez
    Laura de la Puente-Ovejero
    Iker Garcia-Jimenez
    Gabriela González-Iglesias
    Irene Larrañaga-Aiestaran
    Andrea López-Martínez
    Javier Poyatos-García
    Estíbaliz Ruiz-Del-Yerro
    Federico Gonzalez
    Virginia Arechavala-Gomeza
    Scientific Reports, 11
  • [29] Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening
    Soblechero-Martin, Patricia
    Albiasu-Arteta, Edurne
    Anton-Martinez, Aina
    de la Puente-ovejero, Laura
    Garcia-Jimenez, Iker
    Gonzalez-Iglesias, Gabriela
    Larranaga-Aiestaran, Irene
    Lopez-Martinez, Andrea
    Poyatos-Garcia, Javier
    Ruiz-Del-Yerro, Estibaliz
    Gonzalez, Federico
    Arechavala-Gomeza, Virginia
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [30] Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach
    Tremblay, Jacques P.
    Lyombe-Engembe, Jean-Paul
    Duchene, Benjamin
    Ouellet, Dominique L.
    MOLECULAR THERAPY, 2016, 24 (11) : 1888 - 1889
12345